Clinical Trials Logo

Hypogonadotropic Hypogonadism clinical trials

View clinical trials related to Hypogonadotropic Hypogonadism.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05971836 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

The Molecular Basis of Inherited Reproductive Disorders

Start date: January 21, 2021
Phase:
Study type: Observational

The goal of this study is to learn more about the genes that control puberty and reproduction in humans.

NCT ID: NCT05896293 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Kisspeptin Administration Subcutaneously to Patients With IHH

Start date: February 3, 2023
Phase: Phase 2
Study type: Interventional

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Gonadotropin-releasing hormone (GnRH) may be administered subcutaneously (SC) for approximately six days in a pulsatile fashion, in order to prime the pituitary gland. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time. Funding Source: FDA OOPD

NCT ID: NCT05808647 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Low Energy Availability and Pituitary Function (LEAP Study)

LEAP
Start date: April 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about reproductive hormones and if they change in response to 5-days eating an individualized, standardized diet at two levels: energy balance and low energy intake.

NCT ID: NCT05633966 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

KASPR
Start date: December 16, 2022
Phase: Phase 1
Study type: Interventional

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.

NCT ID: NCT05184374 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy. The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient. Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis. GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH. After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation test, which is conducive to the formulation of the following treatment. GnRH pump can pulse subcutaneous injection of gonadorelin, which can be used as the extended provocation test.

NCT ID: NCT04648969 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

NCT ID: NCT02880280 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism

Start date: August 2016
Phase: Phase 4
Study type: Interventional

Observe the therapeutic efficacy of human menopausal gonadotropin combining with human chorionic gonadotropin in adolescent boys with congenital hypogonadotropic hypogonadism.

NCT ID: NCT02705014 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome

Start date: January 2016
Phase: N/A
Study type: Interventional

To investigate the hormone response of hypothalamic-pituitary-gonad axis and spermatogenesis in male pituitary stalk interruption syndrome patients by pulsatile GnRH therapy.

NCT ID: NCT01952782 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Neuropeptides in Human Reproduction

Start date: April 30, 2014
Phase: Phase 1
Study type: Interventional

The investigators are seeking healthy volunteers and volunteers with reproductive disorders for the study of the role of dynorphin in the reproductive system. Dynorphin is a naturally occurring opioid hormone that is blocked by naloxone. We hypothesize that naloxone, by blocking dynorphin, will stimulate production of gonadotropin-releasing hormone (GnRH) and kisspeptin, two other naturally occurring reproductive hormones.

NCT ID: NCT01601171 Recruiting - Clinical trials for Cleft Lip and Palate

Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate

Start date: March 2012
Phase:
Study type: Observational

The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.